Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

Giacomo Bregni , Caroline Vandeputte , Andrea Pretta , Chiara Senti , Elena Trevisi , Elena Acedo Reina , Pashalina Kehagias , Gabriel Liberale , Luigi Moretti , Maria Antonietta Bali , Pieter Demetter , Patrick Flamen , Javier Carrasco , Lionel D'Hondt , Karen Geboes , Yeter Gokburun , Marc Peeters , Marc Van den Eynde , Jean-Luc Van Laethem , Philippe Vergauwe , Camille Anastasia Chapot , Marc Buyse , Amelie Deleporte , Alain Hendlisz & Francesco Sclafani

[1]  Youngchul Kim,et al.  A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. , 2022, European journal of cancer.

[2]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[3]  S. Nomura,et al.  Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[4]  T. Conroy,et al.  Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. , 2020, Journal of Clinical Oncology.

[5]  S. Nomura,et al.  Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Deng,et al.  Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma , 2019, Clinical Cancer Research.

[7]  S. Chiang,et al.  Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers , 2018, Cancer Immunology, Immunotherapy.

[8]  N. Shepherd,et al.  Standards and datasets for reporting cancers Dataset for histopathological reporting of colorectal cancer December 2017 , 2018 .

[9]  D. Zopf,et al.  1198PImmunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer , 2017 .

[10]  S. Lucas,et al.  Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies , 2017, Front. Immunol..

[11]  H. Johansson,et al.  Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. , 2017, The Lancet. Oncology.

[12]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[13]  R. Grützmann,et al.  PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. , 2016, European journal of cancer.

[14]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[15]  L. Påhlman,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Andreola,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.